{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:29:36Z","timestamp":1695004176087},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bpgastro.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.bpg.2014.04.007","type":"journal-article","created":{"date-parts":[[2014,5,4]],"date-time":"2014-05-04T20:46:53Z","timestamp":1399236413000},"page":"485-496","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunisations in Crohn's disease: Who? Why? What? When?"],"prefix":"10.1016","volume":"28","author":[{"given":"F.","family":"Magro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2014.04.007_bib1","series-title":"A\u00a0short history of vaccination","author":"Plotkin","year":"2004"},{"issue":"8","key":"10.1016\/j.bpg.2014.04.007_bib2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.bpg.2014.04.007_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/MOG.0b013e3283463b45","article-title":"Defective innate immunity in inflammatory bowel disease: a Crohn's disease exclusivity?","volume":"27","author":"Marks","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2014.04.007_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00054725-200409000-00028","article-title":"Guidelines for immunizations in patients with inflammatory bowel disease","volume":"10","author":"Sands","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.bpg.2014.04.007_bib5","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","article-title":"Vaccinations in patients with immune-mediated inflammatory diseases","volume":"49","author":"Rahier","year":"2010","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.bpg.2014.04.007_bib6","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/ajg.2009.733","article-title":"A\u00a0practical guide to vaccinating the inflammatory bowel disease patient","volume":"105","author":"Wasan","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"7\u20138","key":"10.1016\/j.bpg.2014.04.007_bib7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3109\/00365521.2011.574734","article-title":"The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines","volume":"46","author":"Wilckens","year":"2011","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"10.1016\/j.bpg.2014.04.007_bib8","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/ibd.21667","article-title":"Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge","volume":"17","author":"Wasan","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.bpg.2014.04.007_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.MIB.0000436277.13917.c4","article-title":"Initial disease course and treatment in an inflammatory bowel disease inception cohort in europe: the ECCO-EpiCom cohort","volume":"20","author":"Burisch","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2014.04.007_bib10","first-page":"8","article-title":"Targeting vaccines to specific clusters of people","author":"Grabenstein","year":"1999","journal-title":"Hosp Pharm"},{"issue":"12","key":"10.1016\/j.bpg.2014.04.007_bib11","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","article-title":"Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2014.04.007_bib12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1751-7915.2011.00283.x","article-title":"Vaccination in the elderly","volume":"5","author":"Derhovanessian","year":"2012","journal-title":"Microb Biotechnol"},{"issue":"Suppl. 5","key":"10.1016\/j.bpg.2014.04.007_bib13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1469-0691.2012.03944.x","article-title":"Vaccines for the elderly","volume":"18","author":"Weinberger","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"RR-15","key":"10.1016\/j.bpg.2014.04.007_bib14","first-page":"1","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Kroger","year":"2006","journal-title":"MMWR Recomm Rep"},{"issue":"17","key":"10.1016\/j.bpg.2014.04.007_bib15","first-page":"1856","article-title":"FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine","volume":"306","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bpg.2014.04.007_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ibd.21688","article-title":"Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines","volume":"18","author":"Dotan","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.bpg.2014.04.007_bib17","first-page":"69","article-title":"Defective memory B-cell formation in patients with inflammatory bowel-disease following tetanus toxoid booster immunization","volume":"24","author":"Brogan","year":"1987","journal-title":"J\u00a0Clin Lab Immunol"},{"issue":"8","key":"10.1016\/j.bpg.2014.04.007_bib18","first-page":"504","article-title":"Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression","volume":"8","author":"Dezfoli","year":"2012","journal-title":"Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2014.04.007_bib19","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1365-2036.2012.05110.x","article-title":"Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2014.04.007_bib20","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10620-011-1980-8","article-title":"Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls","volume":"57","author":"Altunoz","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.bpg.2014.04.007_bib21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1056\/NEJM199701163360307","article-title":"Drug therapy - vaccines to prevent viral hepatitis","volume":"336","author":"Lemon","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"7\u20138","key":"10.1016\/j.bpg.2014.04.007_bib22","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0264-410X(01)00432-7","article-title":"A\u00a0new accelerated vaccination schedule for rapid protection against hepatitis A and B","volume":"20","author":"Nothdurft","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.bpg.2014.04.007_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1708-8305.2006.00106.x","article-title":"Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule","volume":"14","author":"Connor","year":"2007","journal-title":"J\u00a0Travel Med"},{"issue":"5","key":"10.1016\/j.bpg.2014.04.007_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0264-410X(89)90157-6","article-title":"Effect of anatomic injection site, age and smoking on the immune-response to hepatitis-B vaccination","volume":"7","author":"Shaw","year":"1989","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.bpg.2014.04.007_bib25","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1001\/jama.1985.03360220053027","article-title":"Obesity as a predictor of poor antibody-response to hepatitis-B plasma vaccine","volume":"254","author":"Weber","year":"1985","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.bpg.2014.04.007_bib26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1056\/NEJM198909143211103","article-title":"Genetic prediction of nonresponse to hepatitis-B vaccine","volume":"321","author":"Alper","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.bpg.2014.04.007_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0749-3797(98)00003-8","article-title":"Immunogenicity of hepatitis B vaccines \u2013 implications for persons at occupational risk of hepatitis B virus infection","volume":"15","author":"Averhoff","year":"1998","journal-title":"Am J Prev Med"},{"issue":"24","key":"10.1016\/j.bpg.2014.04.007_bib28","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1001\/jama.1993.03510240047030","article-title":"Risk-factors for lack of detectable antibody following hepatitis-B vaccination of Minnesota health-care workers","volume":"270","author":"Wood","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.bpg.2014.04.007_bib29","first-page":"39","article-title":"Overview of clinical-studies with hepatitis-B vaccine made by recombinant-DNA","volume":"13","author":"Zajac","year":"1986","journal-title":"J\u00a0Infect"},{"issue":"RR-16","key":"10.1016\/j.bpg.2014.04.007_bib30","first-page":"1","article-title":"A\u00a0comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.bpg.2014.04.007_bib31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/infdis\/175.3.678","article-title":"A\u00a0comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S-1, and pre-S-2 particles for revaccination of healthy adult nonresponders","volume":"175","author":"Bertino","year":"1997","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.bpg.2014.04.007_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1086\/589722","article-title":"Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine","volume":"198","author":"Cardell","year":"2008","journal-title":"J\u00a0Infect Dis"},{"issue":"50","key":"10.1016\/j.bpg.2014.04.007_bib33","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1016\/j.vaccine.2005.03.060","article-title":"Hepatitis A virus infection in the United States: serologic results from the third National Health and Nutrition Examination Survey","volume":"23","author":"Bell","year":"2005","journal-title":"Vaccine"},{"issue":"9389","key":"10.1016\/j.bpg.2014.04.007_bib34","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0140-6736(03)14418-2","article-title":"Hepatitis A booster vaccination: is there a need?","volume":"362","author":"Van Damme","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bpg.2014.04.007_bib35","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ibd.21465","article-title":"Immunogenecity of hepatitis a vaccine in pediatric patients with inflammatory bowel disease","volume":"17","author":"Radzikowski","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.bpg.2014.04.007_bib36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/infdis\/148.6.1033","article-title":"Serum neutralizing antibody-response to hepatitis-A virus","volume":"148","author":"Lemon","year":"1983","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.bpg.2014.04.007_bib37","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/j.1572-0241.1999.01150.x","article-title":"Immunogenicity of hepatitis A vaccine in decompensated liver disease","volume":"94","author":"Dumot","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2014.04.007_bib38","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00007890-200107270-00019","article-title":"Safety and efficacy of hepatitis A vaccination in liver transplantation recipients","volume":"72","author":"Arslan","year":"2001","journal-title":"Transplantation"},{"issue":"RR-07","key":"10.1016\/j.bpg.2014.04.007_bib39","first-page":"1","article-title":"Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices\u2013United States, 2013\u20132014","volume":"62","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"10.1016\/j.bpg.2014.04.007_bib40","first-page":"1203","article-title":"Immunization of patients with rheumatoid-arthritis against influenza \u2013 a study of vaccine safety and immunogenicity","volume":"21","author":"Chalmers","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.bpg.2014.04.007_bib41","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2011.11.109","article-title":"Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review","volume":"30","author":"Agarwal","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.bpg.2014.04.007_bib42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.cgh.2007.02.035","article-title":"Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease","volume":"5","author":"Mamula","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2014.04.007_bib43","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ajg.2008.120","article-title":"Immune response to influenza vaccine in children with inflammatory bowel disease","volume":"104","author":"Lu","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"34","key":"10.1016\/j.bpg.2014.04.007_bib44","first-page":"1102","article-title":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23)","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.bpg.2014.04.007_bib45","doi-asserted-by":"crossref","first-page":"A68","DOI":"10.1016\/S0016-5085(08)60319-4","article-title":"TNF blockers and immunomodulators impair antibody responses to pneumococcal polysaccharide vaccine (Ppv) in patients with inflammatory bowel disease (IBD)","volume":"134","author":"Melmed","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2014.04.007_bib46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ajg.2009.523","article-title":"Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease","volume":"105","author":"Melmed","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2014.04.007_bib47","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ibd.21800","article-title":"Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study","volume":"18","author":"Fiorino","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.bpg.2014.04.007_bib48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/COH.0b013e328347335d","article-title":"Human papillomavirus, cancer and vaccination","volume":"6","author":"Heard","year":"2011","journal-title":"Curr Opin Hiv Aids"},{"key":"10.1016\/j.bpg.2014.04.007_bib49","first-page":"9","article-title":"Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients","author":"Park","year":"2011","journal-title":"World J Surg Oncol"},{"issue":"6","key":"10.1016\/j.bpg.2014.04.007_bib50","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.bpg.2014.04.007_bib51","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1572-0241.2007.01582.x","article-title":"Higher incidence of abnormal pap smears in women with inflammatory bowel disease","volume":"103","author":"Kane","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2014.04.007_bib52","first-page":"212A","article-title":"Cervical squamous lesions associated with ulcerative colitis","volume":"82","author":"Tamas","year":"2002","journal-title":"Lab Invest"},{"issue":"38","key":"10.1016\/j.bpg.2014.04.007_bib53","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.3748\/wjg.v12.i38.6167","article-title":"Abnormalities of uterine cervix in women with inflammatory bowel disease","volume":"12","author":"Bhatia","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2014.04.007_bib54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2008.10.021","article-title":"Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study","volume":"136","author":"Singh","year":"2009","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.bpg.2014.04.007_bib55","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/ibd.20959","article-title":"Lack of association between cervical dysplasia and IBD: a large case-control study","volume":"15","author":"Lees","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"20","key":"10.1016\/j.bpg.2014.04.007_bib56","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease C, Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"10.1016\/j.bpg.2014.04.007_bib57","first-page":"630","article-title":"Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease C","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.bpg.2014.04.007_bib58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/0003-4819-150-1-200901060-00008","article-title":"Recommended adult immunization schedule: United States, 2009*","volume":"150","author":"Advisory Committee on Immunization P","year":"2009","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.bpg.2014.04.007_bib59","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/S0016-5085(11)60643-4","article-title":"Immune response to human papillomavirus vaccine (Gardasil) in girls and young women with inflammatory bowel disease","volume":"140","author":"Lu","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2014.04.007_bib60","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013 summary recommendations of the advisory committee on immunization practices (ACIP)","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.bpg.2014.04.007_bib61","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1159\/000320412","article-title":"Vaccines and inflammatory bowel disease","volume":"28","author":"Kotton","year":"2010","journal-title":"Dig Dis"},{"issue":"5","key":"10.1016\/j.bpg.2014.04.007_bib62","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2014.04.007_bib63","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/j.1572-0241.2004.41389_7.x","article-title":"disseminated primary varicella after initiation of infliximab for Crohn's disease","volume":"99","author":"Leung","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2014.04.007_bib64","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","article-title":"The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature","volume":"159","author":"Domm","year":"2008","journal-title":"Br J Dermatol"},{"issue":"RR-5","key":"10.1016\/j.bpg.2014.04.007_bib65","first-page":"1","article-title":"Advisory committee on immunization practices centers for D, control, prevention. Prevention of herpes zoster: recommendations of the Advisory committee on immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"10.1016\/j.bpg.2014.04.007_bib66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"3","author":"Rahier","year":"2009","journal-title":"J\u00a0Crohns Colitis"},{"issue":"12","key":"10.1016\/j.bpg.2014.04.007_bib67","first-page":"212","article-title":"FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella","volume":"61","author":"Centers for Disease C, Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.bpg.2014.04.007_bib68","series-title":"ZOSTAVAX (R) package insert","author":"MERK","year":"2006"},{"issue":"12","key":"10.1016\/j.bpg.2014.04.007_bib69","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/ibd.20532","article-title":"Management of the pregnant IBD patient","volume":"14","author":"Dubinsky","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.bpg.2014.04.007_bib70","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ibd.21583","article-title":"Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy","volume":"17","author":"Schnitzler","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.bpg.2014.04.007_bib71","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental Transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2014.04.007_bib72","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2036.2011.04617.x","article-title":"High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy","volume":"33","author":"Zelinkova","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2014.04.007_bib73","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","article-title":"Dutch Delta IBDG. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure","volume":"11","author":"Zelinkova","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2014.04.007_bib74","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2013.171","article-title":"Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease","volume":"108","author":"Gisbert","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"RR-2","key":"10.1016\/j.bpg.2014.04.007_bib75","first-page":"1","article-title":"Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"58","author":"Cortese","year":"2009","journal-title":"MMWR Recomm Rep"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691814000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691814000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T03:05:07Z","timestamp":1565406307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691814000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1521691814000511"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2014.04.007","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunisations in Crohn's disease: Who? Why? What? When?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2014.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}